Literature DB >> 10399629

Disappearance curves for tumor markers after resection of intrathoracic malignancies.

T Yoshimasu1, S Maebeya, T Suzuma, T Bessho, H Tanino, J Arimoto, T Sakurai, Y Naito.   

Abstract

Determination of the standard elimination kinetics of tumor markers will be helpful in the diagnosis of malignancies. We analyzed the disappearance curves for serum tumor marker levels after resection of intrathoracic malignancies. Serum levels of CEA, SLX, AFP, CA 19-9, SCC, TPA and CYFRA were measured several times after surgery in a total of 40 patients. To obtain precise biological half-lives, we applied non-linear least square analysis, taking into consideration the possibility of residual tumor cells. Disappearance curves were monophasic for CEA, SCC, TPA, CYFRA and SLX and biphasic for CA 19-9 and AFP. Temporary elevation of serum levels after surgery was observed for SCC, TPA and CYFRA. The average half-lives of CEA, SLX, SCC, TPA and CYFRA were 1.5 days, 2.7 days, 2.2 hours, 2.5 hours and 1.5 hours, respectively. The average half-life of CA 19-9 was 0.5 days in the first compartment and 4.3 days in the second compartment, while that of AFP was 1.0 days and 6.3 days, respectively. These values will be helpful in the interpretation of serum tumor marker levels after surgery.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399629     DOI: 10.1177/172460089901400207

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  20 in total

Review 1.  Tumor DNA: an emerging biomarker in head and neck cancer.

Authors:  Joseph A Bellairs; Rifat Hasina; Nishant Agrawal
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

Review 2.  Liquid biopsies: genotyping circulating tumor DNA.

Authors:  Luis A Diaz; Alberto Bardelli
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

Review 3.  Developing biomarker-specific end points in lung cancer clinical trials.

Authors:  Joel W Neal; Justin F Gainor; Alice T Shaw
Journal:  Nat Rev Clin Oncol       Date:  2014-12-23       Impact factor: 66.675

Review 4.  Liquid biopsy: unlocking the potentials of cell-free DNA.

Authors:  David Chu; Ben Ho Park
Journal:  Virchows Arch       Date:  2017-05-02       Impact factor: 4.064

5.  A Serum Level of Squamous Cell Carcinoma Antigen as a Real-Time Biomarker of Atopic Dermatitis.

Authors:  Masaki Shimomura; Yuka Okura; Yutaka Takahashi; Ichiro Kobayashi
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2021-08-19       Impact factor: 0.885

6.  Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome.

Authors:  Linh Pham; Takafumi Nakamura; A Gabriela Rosales; Stephanie K Carlson; Kent R Bailey; Kah-Whye Peng; Stephen J Russell
Journal:  J Gene Med       Date:  2009-03       Impact factor: 4.565

7.  Mutant KRAS Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.

Authors:  Ruth Perets; Orli Greenberg; Talia Shentzer; Valeria Semenisty; Ron Epelbaum; Tova Bick; Shada Sarji; Ofer Ben-Izhak; Edmond Sabo; Dov Hershkovitz
Journal:  Oncologist       Date:  2018-01-25

8.  Onset of liver metastasis after histologically curative resection of pancreatic cancer.

Authors:  Katsuhiko Inoue; Takehisa Hiraoka; Keiichiro Kanemitsu; Hiroshi Takamori; Tatsuya Tsuji; Michio Kawasuji
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

9.  Prognostic value of postoperative CEA clearance in rectal cancer patients with high preoperative CEA levels.

Authors:  Jeong Yeon Kim; Nam Kyu Kim; Seung Kook Sohn; Yong Wan Kim; Kim Jin Soo Kim; Hyuk Hur; Byung Soh Min; Chang Hwan Cho
Journal:  Ann Surg Oncol       Date:  2009-08-06       Impact factor: 5.344

10.  A case of raised CA 19-9 in a patient with desmoplastic fibroblastoma of the upper limb.

Authors:  Kumaran Rasappan; Leanne Kayla Rebecca Mei-Yi Shaw; Lester Wai Mon Chan; Khoon Leong Chuah; Mathew Hern Wang Cheng
Journal:  Int Cancer Conf J       Date:  2021-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.